ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: These findings demonstrated that targeting the BCR-ABL gene caused a dramatic disruption in DNA sequence and protein suppression and eventually suppressed cell viability in CML cells, implying that BCR-ABL gene editing would be a sufficient and effective anticancer strategy.